The 1 most recent market catalysts affecting $TPUS, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 19, 2026
Corporate Catalyst
Bullish
Impact 85
Shares of Tempus AI are trading higher amid possible sympathy with Merck and Moderna after the Phase 3 INTerpath-001 trial met its primary and a key secondary endpoint. The results may also boost sentiment around Tempus AI’s planned $1.5 billion acquisition of Personalis, whose genomic tumor-profiling technology supports the personalized vaccine used in the trial.
The successful Phase 3 trial for Merck and Moderna's personalized vaccine is a major positive for the biotechnology sector, particularly for companies involved in genomic profiling…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.